Business Wire

Oxford Nanopore Announces £100 Million ($140M) Fundraising from Global Investors

Del

Oxford Nanopore Technologies Ltd, the company behind the only portable real-time DNA/RNA sequencer, MinION, has raised £100M ($140M) in new investment. Funds were raised from global investors including GIC (Singapore), China Construction Bank International (CCBI, China), Hostplus (Australia), and existing investors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180319006158/en/

Oxford Nanopore’s novel DNA/RNA sequencing technology: the portable MinION is now being joined by ot ...

Oxford Nanopore’s novel DNA/RNA sequencing technology: the portable MinION is now being joined by other formats including high-throughput, on-demand PromethION and single-test Flongle (Graphic: Business Wire)

The funds will be used to support the Company’s next phase of commercial expansion. This includes a new high-volume, high-tech manufacturing facility in Oxford to meet accelerating demand for Oxford Nanopore’s sequencing technology, and growth of the commercial team that already serves more than 70 countries.

The funds raised will also support R&D as Oxford Nanopore expands its suite of nanopore analysis devices. The currently available pocket MinION and desktop GridION are being joined by high-throughput modular sequencing with PromethION and small, single-test sequencing with Flongle.

This expanded range is designed to address all parts of the existing DNA-sequencing market, as well as enabling new applications that can only be performed with a real-time, scalable, long-read technology. For example, Flongle is designed to enable the rapid real-time genetic analysis of infectious diseases, targeted analyses in precision medicine, food and/or water-safety surveillance, and science education. PromethION will enable large-scale, on-demand sequencing of human, plant, or animal genomes.

Oxford Nanopore technology also uniquely enables direct RNA sequencing, providing full-length transcript and viral genome profiling, precise quantification, the ability to identify modified bases in real time, and simplifying workflows.

Dr Gordon Sanghera, CEO, Oxford Nanopore, said: ‘Our business is moving quickly, from personal sequencers into high-end sequencing and distributed analyses. In recent weeks, both Oxford Nanopore and our customers have shown very high yields of data from PromethION Flow Cells, demonstrating low-cost long-read nanopore sequencing at large scale. Meanwhile, we are driving a change in how scientists and industries access DNA information, by introducing smaller, accessible, low-cost formats, including our forthcoming smartphone sequencer SmidgION. Our investors are ambitious and support our long-term vision: to enable the analysis of any living thing, by anyone, anywhere.

‘We would also like to thank the innovative community of nanopore users, who have been instrumental in driving new uses for our products.’

Theresa May, Prime Minister of the UK, said: ‘I’m pleased that such a pioneering British business has obtained the investment they need to grow, creating thousands more jobs and continuing ground-breaking research in this field here in the UK.

‘Through our modern Industrial Strategy we are making sure that Britain remains the natural choice for innovative firms to prosper – investing in the future of our country.’

Bryan Yeo, Chief Investment Officer of Public Equities at GIC, said: ‘Oxford Nanopore has a unique business model of providing accessible, real-time DNA-analysis technologies that can be applied to pocket-sized or industrial installations. We believe this will continue to drive growth in their user base as well as in new applications for DNA- or RNA-sequencing. This investment reflects our confidence in the global demand outlook for DNA information across many industries over the long term.’

A CCBI spokesperson said ‘Our investment into Oxford Nanopore reflects our view that the high-growth sectors such as DNA sequencing have a promising future and is also underpinned by our strong belief that sequencing technology has the huge potential to enable new applications across life science research, healthcare, food and other industries in China. Following the global industrial development trend, CCBI will continue to focus its strategic investment on new economy sectors including biotechnology and AI, etc.’

David Elia, CEO of Hostplus said: ‘We are excited by the possibilities of Oxford Nanopore technology to develop new applied markets and to revolutionise testing. This could be in oncology, infectious disease, reproductive health and blood screening.’

Oxford Nanopore is headquartered in the UK (Oxford and Cambridge) with a commercial presence in New York, Cambridge (US), China, Japan, France, and Germany. New headquarters recently opened in Oxford and new operations are now being opened in Shanghai and San Francisco.

Oxford Nanopore also announces the forthcoming construction of a new bespoke 34,000sqft manufacturing facility on the Harwell Science and Innovation Campus. This new facility represents a significant increase in Oxford Nanopore’s manufacturing capabilities, replicating and growing the manufacturing processes developed over the years within the Science and Technology Facilities Council (STFC) environment. Including high-specification clean rooms, laboratories, office space, and logistics areas, the new addition to Oxford Nanopore’s operations will be used to manufacture and distribute our DNA/RNA sequencing products in one purpose-built facility. This facility has been made possible through the continued support of the STFC at Harwell, the use of the high-tech facilities managed by the Innovations Technology Access Centre (ITAC), and working with the Harwell Campus Joint Venture team.

Note: The placement of ordinary shares in the Company under this fundraising does not constitute an offer of the Company’s shares to the public. No shares in the Company will be offered or sold to any person except in circumstances which have not resulted and will not result in an offer to the public.

-ends-

Images available at: https://nanoporetech.com/about-us/for-the-media

B-roll available on request

About Oxford Nanopore

Oxford Nanopore Technologies Ltd has developed the world’s only portable, real-time DNA/RNA sequencer. The company is headquartered in Oxford, UK, with expanding global operations.

The MinION is a portable, real-time, long-read, low-cost device that has been designed to bring easy biological analyses to anyone, whether in scientific research or a range of real-world applications such as disease/pathogen surveillance, environmental monitoring, food-chain surveillance, self-quantification, or even microgravity biology. Commercially available since 2015, the MinION is in use by a thriving community of scientists in more than 70 countries, where it is enabling myriad applications within the traditional laboratory environment and in the field.

Nanopore sequencing technology is fully scalable. The GridION X5 is a desktop device that includes compute module and the ability to run up to five MinION Flow Cells. The high-throughput, high-sample-number PromethION has now been released in the PromethION Early Access Programme (PEAP).

PromethION is nearly 300 times more powerful than the MinION, but modular and on-demand. In early 2018, Oxford Nanopore is producing more than 150Gb per PromethION Flow Cell; – PromethION is designed to run up to 48 Flow Cells. Customers are producing 70–100Gb per PromethION Flow Cell using clinical samples and plant samples as well as test samples. This shows that PromethION can deliver a sub-$1,000 human genome on long-read nanopore data alone.

Oxford Nanopore aims to make DNA-based analyses easy enough for any user and so we are focused on simple sample preparation and data-analysis processes. For sample preparation, this includes a 5–10-minute sample prep kit and VolTRAX, a rapid, programmable, automated USB sample-preparation device designed to prepare DNA for addition to a nanopore sequencing device. The Company is also developing a single-test nanopore sequencing adapter for MinION (Flongle) and a smartphone sequencer, SmidgION.

About GIC

GIC is a leading global investment firm established in 1981 to manage Singapore’s foreign reserves. A disciplined long-term value investor, GIC is uniquely positioned for investments across a wide range of asset classes, including equities, fixed income, private equity, real estate, and infrastructure. GIC has investments in over 40 countries and has been investing in emerging markets for more than two decades. Headquartered in Singapore, GIC employs over 1,400 people across 10 offices in key financial cities worldwide. For more information about GIC, please visit www.gic.com.sg.

About CCBI

CCB International (Holdings) Limited (“CCBI”) is a financial and investment services company owned by China Construction Bank (“CCB”). Apart from its home base on the mainland and its headquarter in Hong Kong, CCBI manages its subsidiaries in the world financial centres such as New York, Singapore, and London, backed up by the CCB global network. CCBI provides a comprehensive financial and investment services value chain that offers a full range of products and services including sponsoring and underwriting, corporate mergers and acquisitions, refinancing for listed companies, direct investment, asset management, securities brokerage, market research, futures and commodities business.

About Hostplus

Hostplus is the national superannuation fund for those who live and love Australian hospitality, tourism, recreation, and sport. The Australian Hotels Association and United Voice jointly established the fund in 1987. Hostplus is one of the largest in the country with over one million members, 168,000 employers and AU$30 billion in funds under management.

Contact information

Oxford Nanopore
Zoe McDougall
media@nanoporetech.com
Website: https://nanoporetech.com/
Twitter @nanopore
WeChat: nanoporetech

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Lehman Brothers Treasury Announces Plans for Partial Wind-Down14.12.2018 17:41Pressemelding

Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Kramer Levin Naftalis & Frankel LLP, announced that LBT is planning a final cash distribution to its creditors. Professional holders of eligible notes will have the option to retain their investment by electing to receive substitute notes of one (or a few) series. Such election shall take place through a solicitation process. As a consequence, LBT will be able to reduce the number of series of notes outstanding from more than 3,700 to one or a few. Noteholders electing to receive substitute notes will be afforded the same economic entitlement to distributions received by LBT from Lehman Brothers Holdings Inc. (“LBHI”) through the substitute notes. The substitute notes will be denominated in U.S. dollars and future distributions will be made in U.S. dollars only. Noteholders who are not professional investors, or hold notes that are not eligible for substitution, or do not elect to receive substitut

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD14.12.2018 17:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin) and recommended its approval in combination with AVD in adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma. ADCETRIS is currently not approved as a therapy for previously untreated Hodgkin lymphoma in Europe. “For a large number of previously untreated Hodgkin lymphoma patients diagnosed with Stage IV disease, progression will occur with current treatments, highlighting a true unmet need in this population,” said Anna Sureda, M.D., Ph.D., Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d'Oncologia - Hospital Duran i Reynals. “In the ECHELON-1 cl

Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules14.12.2018 15:42Pressemelding

Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN), a leader in hemp extraction and innovative CBD products for the wellness market, enters the Coffee segment, an industry expected to reach revenues of $46 Billion in 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181214005308/en/ Experience a cup of Chill (Photo: Business Wire) Produced in accordance with a universal K-Cup design, these pods fit in almost all modern single cup coffee makers, making it an easily integrated enhancement to any environment, delivering 25mgs of CBD in a tasty favorite beverage at less than $5 per cup. This new line of premium Chill Coffee Capsules was recently added to the Company’s broad range of cannabinoid and natural hemp products. Each box comes with 4 individual capsules in original chill coffee, decaf chill coffee, chill black tea, and chill green tea flavors. The unit price for each box is $10.00

Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth14.12.2018 14:00Pressemelding

Residence- and citizenship-by-investment programs have firmly established themselves over the past few years as the new frontier in terms of freedom, flexibility, and future-readiness, both for the countries issuing these programs and for the individual investors participating in them. The societal and economic value these programs generate is undisputed. The investment migration industry as a whole is currently grossing roughly USD 18 billion per year, with an expectation that it will hit the USD 20 billion mark very soon. Foreign direct investment (FDI) is now considered the lifeblood of economic growth for many developing and recovering smaller countries around the world. As such, the number of investment migration programs has been increasing rapidly, from just a handful of programs in the 1980s and 1990s to over 100 countries that now have investment migration provisions in their laws. There are more than 60 active programs today, with Moldova and Montenegro — both fast-growing Eu

Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 09:07Pressemelding

Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha

Alps Electric to Exhibit at CES 2019 as Alps Alpine for the First Time14.12.2018 07:58Pressemelding

Japanese comprehensive electronic components manufacturer Alps Electric Co., Ltd. (TOKYO:6770) (Ota-ku, Tokyo; President: Toshihiro Kuriyama) will exhibit at CES 2019, to open at the Las Vegas Convention and World Trade Center in Las Vegas, Nevada, in the United States on January 8. Alps Electric will be taking part as a new company, Alps Alpine Co., Ltd., for the first time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181213006022/en/ Alps Alpine's new touch input device for automotive (Graphic: Business Wire) At CES 2019, an exposition of cutting-edge technologies brought together from around the world, Alps Electric will present a variety of technologies in response to the major trends in automotive development referred to as “CASE”—namely connected cars, autonomous driving, sharing and services, and electric vehicles. Making its first appearance at the show as a new company following its business integration with subs